Suzanne Johnson - Pfizer Independent Director
| PFE Stock | MXN 432.00 6.00 1.37% |
Director
Ms. Suzanne M. Nora Johnson, J.D., is an Independent Director of Pfizer Inc., since September 27, 2007. She is Retired Vice Chairman, Goldman Sachs Group, Inc., since 2007. During her 21year tenure with Goldman Sachs, served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care. Director of American International Group, Inc., Intuit Inc. and Visa Inc. Vice Chair, Board of Trustees of The Brookings Institution CoChair of the Board of Trustees of the Carnegie Institution of Washington CoChair of the Board of Trustees of the University of Southern California and member of the Global Agenda Council on the Future of Financial and Monetary Systems for the World Economic Forum. Ms. Nora Johnsons careers in law and investment banking, including serving in various leadership roles at Goldman Sachs, provide valuable business experience and critical insights into the roles of the law and finance when evaluating strategic transactions. Ms. Nora Johnson also brings financial expertise to the Board, providing an understanding of financial statements, corporate finance, accounting and capital markets since 2007.
| Age | 60 |
| Tenure | 17 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1332 % which means that it generated a profit of $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3687 %, meaning that it generated $0.3687 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Vivienne Cox | GlaxoSmithKline plc | 59 | |
| Ann Fudge | Novartis AG | 68 | |
| Marcus Wallenberg | AstraZeneca PLC | 63 | |
| Lynn Elsenhans | GlaxoSmithKline plc | 61 | |
| Pierre Landolt | Novartis AG | 70 | |
| William Perez | Johnson Johnson | 70 | |
| Susan Lindquist | Johnson Johnson | 65 | |
| Baroness Vadera | AstraZeneca PLC | 52 | |
| Mary Beckerle | Johnson Johnson | 64 | |
| Bridgette Heller | Novartis AG | 58 | |
| Frederick Waddell | AbbVie Inc | 65 | |
| Eugene Washington | Johnson Johnson | 67 | |
| Genevieve Berger | AstraZeneca PLC | 64 | |
| Philip Hampton | GlaxoSmithKline plc | 63 | |
| Shriti Vadera | AstraZeneca PLC | 55 | |
| Jennifer Doudna | Johnson Johnson | 55 | |
| Deryck Maughan | GlaxoSmithKline plc | 67 | |
| Rebecca Roberts | AbbVie Inc | 65 | |
| Frans Houten | Novartis AG | 59 | |
| Ronald Williams | Johnson Johnson | 69 | |
| Ann Cairns | AstraZeneca PLC | 57 | |
Management Performance
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President of Global Established Pharma Bus. | ||
| Jennifer Damico, Controller VP | ||
| Frank DAmelio, CFO and Executive VP of Bus. Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Director | ||
| James Smith, Director | ||
| Christopher CFA, VP Officer | ||
| Dennis Ausiello, Independent Director | ||
| Mikael Dolsten, President - Worldwide Research and Development | ||
| Frances Fergusson, Independent Director | ||
| Stephen Sanger, Independent Director | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| DVM DVM, Chairman CEO | ||
| Geno Germano, Group President of Global Innovative Pharma Bus. | ||
| Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
| Sally Susman, Executive Vice President - Corporate Affairs | ||
| Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Freda LewisHall, Executive Vice President Chief Medical Officer | ||
| Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
| Mikael MD, Dev Research | ||
| Dan Littman, Director | ||
| Ian Read, Chairman, CEO and Chairman of Executive Committee | ||
| James Kilts, Independent Director | ||
| Don Cornwell, Independent Director | ||
| Charles Hill, Executive Vice President - Worldwide Human Resources | ||
| Joseph Echevarria, Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Scott Gottlieb, Director | ||
| Ronald Blaylock, Independent Director | ||
| Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
| Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 5.97 T | |||
| Shares Outstanding | 5.61 B | |||
| Shares Owned By Institutions | 70.47 % | |||
| Price To Earning | 27.15 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 59.69 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |